Skip to main content
Scinai Immunotherapeutics Ltd. logo

Scinai Immunotherapeutics Ltd. — Investor Relations & Filings

Ticker · SCNI ISIN · US09073Q3039 US Manufacturing
Open in API
Filings indexed 468 across all filing types
Latest filing 2023-09-06 Regulatory Filings
Country US United States of America
Listing US SCNI

About Scinai Immunotherapeutics Ltd.

https://www.scinai.com/

Scinai Immunotherapeutics Ltd. is a clinical-stage biopharmaceutical company operating through two complementary business units. Its internal research and development division focuses on developing innovative biological products for inflammation and immunology (I&I), targeting autoimmune and infectious diseases. The core of its therapeutic pipeline is a platform of Alpaca-derived nanosized antibodies (NanoAbs or VHH-antibodies), developed for conditions such as psoriasis and asthma. The company's second unit, Scinai Bioservices, is a Contract Development and Manufacturing Organization (CDMO). It provides end-to-end services to biotech companies, supporting drug development from early research and process development through to cGMP-compliant manufacturing for clinical trials up to Phase 3.

Recent filings

Filing Released Lang Actions
REPORT OF FOREIGN PRIVATE ISSUER
Regulatory Filings Classification · 95% confidence The document is a Form 6-K filing by a foreign private issuer, Scinai Immunotherapeutics Ltd., reporting a corporate name change and including a press release about rebranding. It is a regulatory report submitted under the Securities Exchange Act of 1934, specifically a Form 6-K, which is used for current reports by foreign private issuers. The document is short (1726 characters) and primarily announces a corporate name change and a press release, without containing financial statements or detailed financial data. It does not fit into categories like Annual Report, Interim Report, or Earnings Release. It is a regulatory filing reporting a corporate event. Therefore, the most appropriate classification is Regulatory Filings (RNS).
2023-09-06 English
REPORT OF FOREIGN PRIVATE ISSUER
Investor Presentation Classification · 95% confidence The document is a Form 6-K, which is a report of a foreign private issuer filed with the SEC. It includes an updated presentation about the company's business, referenced as Exhibit 99.1. The text states that the presentation is furnished herewith and incorporated by reference, indicating the document primarily serves to provide an investor presentation rather than a full financial report or other filing type. The document length is short (2104 characters), and it is not a full annual or quarterly report. Therefore, the best classification is Investor Presentation (IP).
2023-09-06 English
PROSPECTUS
Capital/Financing Update Classification · 95% confidence The document is a prospectus filed pursuant to Rule 424(b)(2) for a shelf registration statement allowing the company to offer and sell securities up to $150 million. It includes detailed descriptions of the securities, risk factors, company overview, and terms of the offering. This type of document is related to capital raising activities and financing. It is not an annual report, earnings release, or management discussion. It is a primary offering document for securities issuance. Therefore, it fits the category of Capital/Financing Update (CAP). The document length is substantial and contains detailed offering information, not just an announcement or a brief notice, so it is not RPA or RNS. Confidence is high given the clear identification as a prospectus for securities offering.
2023-08-28 English
Regulatory Filings 2023
Regulatory Filings
2023-08-28 English
REPORT OF FOREIGN PRIVATE ISSUER
Declaration of Voting Results & Voting Rights Announcements Classification · 100% confidence The document is a Form 6-K filed by a foreign private issuer, BiondVax Pharmaceuticals Ltd, reporting on the results of its Annual General Meeting (AGM) held on August 24, 2023. The content includes detailed voting results on various proposals such as re-election of directors, amendments to articles, compensation approvals, and auditor appointments. The document is not a full annual report or financial statement but specifically reports the voting outcomes of the AGM. This matches the definition of 'Declaration of Voting Results & Voting Rights Announcements (DVA)'. The document length (9127 characters) and detailed vote counts support that this is a full voting results announcement rather than a brief notice or a report publication announcement.
2023-08-24 English
Regulatory Filings 2023
Regulatory Filings Classification · 95% confidence The document is a letter addressed to the SEC requesting acceleration of the effectiveness of a Registration Statement on Form F-3. It references a specific filing (Form F-3) and requests a procedural action related to the registration statement's effective date. The content is a formal regulatory communication rather than a financial report or detailed filing. The document length is short (1240 characters), and it does not contain financial data or detailed report content. Therefore, it is best classified as a Regulatory Filing (RNS), which covers general regulatory announcements and compliance documents that do not fit other categories.
2023-08-23 English

Browse filings by year

13 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.